Iter-4360dd15-0109-transcript
第 109 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 PMID original human trial primary endpoint"}) → call list_recent({"n":8})
→ call list_by_tag({"limit":20,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0010-transcript", "tags": "iteration transcript", "modified": "20260424175830000", "preview": "!! 第 10 轮执行轨迹
→ cal"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹 → call search_memory({\\\"limit"}, {"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹 【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0108-reflection", "modified": "20260424214200000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424214200000", "tags": "pinned focus"}, {"title": "亚组论文不能当原始试验", "modified": "20260424214200000", "tags": "lesson evidence-chain trial-screening"}, {"title": "Iter-4360dd15-0108-transcript", "modified": "20260424214156000", "tags": "iteration transcript"}, {"title": "PMID 24267730 is a subgroup analysis, not the first original human trial", "modified": "20260424214147000", "tags": "fact method 4360dd15 clinical-trials evidence-chain"}, {"title": "Iter-4360dd15-0107-reflection", "modified": "20260424214025000", "tags": "iteration reflection"}, {"title": "别在记忆里绕圈，直接打原始证据", "modified": "20260424214025000", "tags": "lesson evidence-chain screening"}, {"title": "Iter-4360dd15-0107-transcript", "modified": "20260424214019000", "tags": "iteration transcript"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "PMID 24267730 is a subgroup analysis, not the first original human trial", "modified": "20260424214147000"}, {"title": "Iter-4360dd15-0106-four-candidate-audit", "modified": "20260424213752000"}, {"title": "Iter-4360dd15-0104-three-remaining-candidates-are-not-original-first-reports", "modified": "20260424213638000"}, {"title": "Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist", "modified": "20260424213315000"}, {"title": "Iter-4360dd15-0100-human-trial-vs-non-original-screening-of-38310895-references", "modified": "20260424212530000"}, {"title": "Iter-4360dd15-0099-critic-mechanistic-vs-aging-trial", "modified": "20260424212312000"}, {"title": "Iter-4360dd15-0098-EuropePMC-extract-human-trial-PMIDs", "modified": "20260424212055000"}, {"title": "PMID 22367193 is cardiac-repolarization safety, not longevity evidence", "modified": "20260424210833000"}, {"title": "PMID 24691032 is muscle-protein-synthesis endpoint, not longevity evidence", "modified": "20260424210355000"}, {"title": "PMID 22115710 is phase I ocular safety study, not longevity evidence", "modified": "20260424210145000"}, {"title": "PMID 29408453 is feasibility/safety pilot, not direct longevity evidence", "modified": "20260424210012000"}, {"title": "PMID 31761958 is skin-senescence endpoint, not longevity evidence", "modified": "20260424205759000"}, {"title": "PMID 33977284 is RTI incidence endpoint, not direct longevity evidence", "modified": "20260
→ call search_memory({"limit":10,"query":"4360dd15 BOLERO-2 original trial PMID everolimus exemestane phase III NEJM"})
→ call pubmed_search({"limit":10,"query":"BOLERO-2 everolimus exemestane phase 3 trial"})
→ call web_search({"limit":10,"query":"BOLERO-2 everolimus exemestane original trial PMID phase III primary endpoint"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0108-transcript", "tags": "iteration transcript", "modified": "20260424214156000", "preview": "!! 第 108 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 NEXT_FOCUS original human trial\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0010-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424175830000\", \"preview\": \"!! 第 10 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS PMID 10 条候选 研究类型 保留 排除 理由\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"evidence-retrieval clinical-trials\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0051-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424194527000\", \"preview\": \"!! 第 51 轮执行"}, {"title": "Iter-4360dd15-0053-transcript", "tags": "iteration transcript", "modified": "20260424194945000", "preview": "!! 第 53 轮执行轨迹 【tool:pubmed_search】
{"ok": true, "query": "BOLERO-2 everolimus exemestane phase 3 trial", "results": [{"pmid": "39118946", "title": "The role of everolimus in metastatic breast cancer and possibilities of moving forward-a narrative review.", "source": "Ann Transl Med", "pubdate": "2024 Aug 1", "authors": ["Rubovszky G"], "url": "https://pubmed.ncbi.nlm.nih.gov/39118946/"}, {"pmid": "38904918", "title": "BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer.", "source": "Discov Oncol", "pubdate": "2024 Jun 21", "authors": ["Shao ZM", "Cai L", "Wang S", "Hu X", "Shen K", "Wang H", "Li H", "Feng J"], "url": "https://pubmed.ncbi.nlm.nih.gov/38904918/"}, {"pmid": "32962980", "title": "A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.", "source": "Clin Cancer Res", "pubdate": "2020 Dec 1", "authors": ["Prat A", "Tsai YH", "Pascual T", "Paré L", "Adamo B", "Vidal M", "Brasó-Maristany F", "Galván P"], "url": "https://pubmed.ncbi.nlm.nih.gov/32962980/"}, {"pmid": "30679318", "title": "Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.", "source": "Oncologist", "pubdate": "2019 Jul", "authors": ["Prat A", "Brase JC", "Cheng Y", "Nuciforo P", "Paré L", "Pascual T", "Martínez D", "Galván P"], "url": "https://pubmed.ncbi.nlm.nih.gov/30679318/"}, {"pmid": "3061
【tool:web_search】
{"ok": true, "query": "BOLERO-2 everolimus exemestane original trial PMID phase III primary endpoint", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "In this phase 3, randomized trial , we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced ..."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor, exemestane (EXE), significantly prolonged progression-free survival (PFS) in this patient population. Protocol-specified final PFS analyses are presented."}, {"title": "The BOLERO-2 trial: the addition of everolimus to exemestane in the ...", "url": "https://pubmed.ncbi.nlm.nih.gov/22764762/", "snippet": "Abstract The combination of the mTOR inhibitor everolimus with the aromatase inhibitor exemestane was evaluated in the randomized Phase III BOLERO-2 trial . Research has indicated that aberrant signaling through the mTOR pathway is associated with resistance to endocrine therapies."}, {"title":
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/22764762/"})
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/24267730/"})
→ call web_fetch({"max_chars":7000,"url":"https://clinicaltrials.gov/study/NCT00863655"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/22764762/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/24267730/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://clinicaltrials.gov/study/NCT00863655'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call pubmed_search({"limit":5,"query":"22764762"})
→ call pubmed_search({"limit":5,"query":"24267730"})
→ call web_search({"limit":5,"query":"22764762 BOLERO-2 primary endpoint progression-free survival"})
→ call web_search({"limit":5,"query":"24267730 BOLERO-2 subgroup analysis elderly"})
【tool:pubmed_search】
{"ok": true, "query": "22764762", "results": [{"pmid": "22764762", "title": "The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.", "source": "Future Oncol", "pubdate": "2012 Jun", "authors": ["Beaver JA", "Park BH"], "url": "https://pubmed.ncbi.nlm.nih.gov/22764762/"}]}
【tool:pubmed_search】
{"ok": true, "query": "24267730", "results": [{"pmid": "24267730", "title": "Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.", "source": "Clin Breast Cancer", "pubdate": "2013 Dec", "authors": ["Pritchard KI", "Burris HA 3rd", "Ito Y", "Rugo HS", "Dakhil S", "Hortobagyi GN", "Campone M", "Csöszi T"], "url": "https://pubmed.ncbi.nlm.nih.gov/24267730/"}]}
【tool:web_search】
{"ok": true, "query": "22764762 BOLERO-2 primary endpoint progression-free survival", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal ..."}, {"title": "The BOLERO-2 trial: the addition of everolimus to exemestane in the ...", "url": "https://pubmed.ncbi.nlm.nih.gov/22764762/", "snippet": "Research has indicated that aberrant signaling through the mTOR pathway is associated with resistance to endocrine therapies. The BOLERO-2 trial examined the effects on progression-free survival of the addition of everolimus to exemestane in a patient population of postmenopausal, hormone receptor-positive, advanced breast cancer."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) analys
【tool:web_search】
{"ok": true, "query": "24267730 BOLERO-2 subgroup analysis elderly", "results": [{"title": "Safety and efficacy of everolimus with exemestane vs ... - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/24267730/", "snippet": "Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2"}, {"title": "Safety and efficacy of everolimus with exemestane vs. exemestane alone ...", "url": "https://europepmc.org/article/MED/24267730", "snippet": "Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study."}, {"title": "oncology-annual-meeting-2023-poster-hu-subgroup-analysis-of-elderly ...", "url": "https://medically.roche.com/global/en/oncology/oncology-annual-meeting-2023/medical-material/oncology-annual-meeting-2023-poster-hu-subgroup-analysis-of-elderly-patients-pdf.html", "snippet": "Subgroup analysis of elderly patients with diffuse large B-cell lymphoma (DLBCL) in the Phase 3 POLARIX study Authors Hu B, Reagan P, Sehn LH, Sharman JP, Hertzberg M, Zhang H, Kim A, Herbaux C, Molina L, Maruyama D, Smolewski P, Stenner F, Craine V, Kothari R, Hirata J, Sahin D, Sugidono M, Lee C, Tilly H Published date 04 June, 2023 In the Phase 3 POLARIX study, Pola-R-CHP significantly ..."}, {"title": "Subgroup analysis of elderly patients (≥60 years) with diffuse large B ...", "url": "https:
→ call web_search({"limit":10,"query":"\"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer\" PMID"})
→ call web_search({"limit":10,"query":"\"BOLERO-2\" NEJMoa1109653 PMID"})
→ call pubmed_search({"limit":10,"query":"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer"})
【tool:web_search】
{"ok": true, "query": "\"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer\" PMID", "results": [{"title": "Everolimus in postmenopausal hormone-receptor-positive advanced breast ...", "url": "https://www.bordet.be/en/everolimus-postmenopausal-hormone-receptor-positive-advanced-breast-cancer", "snippet": "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer ."}]}
【tool:web_search】
{"ok": true, "query": "\"BOLERO-2\" NEJMoa1109653 PMID", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1109653?articleTools=true", "snippet": "The BOLERO-2 study showed that the addition of everolimus to exemestane significantly improves progression-free survival, with observed medians of 6.9 and 2.8 months, corresponding to a 57% ..."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5705195/", "snippet": "The BOLERO-2 study showed that the addition of everolimus to exemestane significantly improves progression-free survival, with observed medians of 6.9 and 2.8 months, corresponding to a 57% reduction in the hazard ratio."}, {"title": "Everolimus in Combination With Exemestane in the Treatment of ...", "url": "https://clinicaltrials.gov/study/NCT00863655", "snippet": "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole ( BOLERO-2 )"}, {"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR", "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus
【tool:pubmed_search】
{"ok": true, "query": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer", "results": [{"pmid": "39379960", "title": "Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER(+) breast cancer.", "source": "BMC Med", "pubdate": "2024 Oct 8", "authors": ["Zimmer P", "Esser T", "Lueftner D", "Schuetz F", "Baumann FT", "Rody A", "Schneeweiss A", "Hartkopf AD"], "url": "https://pubmed.ncbi.nlm.nih.gov/39379960/"}, {"pmid": "38447007", "title": "Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.", "source": "Int J Cancer", "pubdate": "2024 Jul 1", "authors": ["Lüftner D", "Schuetz F", "Schneeweiss A", "Hartkopf A", "Bloch W", "Decker T", "Uleer C", "Stötzer O"], "url": "https://pubmed.ncbi.nlm.nih.gov/38447007/"}, {"pmid": "37655108", "title": "Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis.", "source": "Front Oncol", "pubdate": "2023", "authors": ["Chao TC", "Tsai YF", "Liu CY", "Lien PJ", "Lin YS", "Feng CJ", "Chen YJ", "Lai JI"], "url": "https://pubmed.ncbi.nlm.nih.gov/37655108/"}, {"pmid": "36823129", "title": "Effectiveness of Changing the Class of Molecularly Targeted Agent after Disease Progression during Initial Molecularly Targeted Therapy for Lu
→ call search_memory({"limit":10,"query":"BOLERO-2 NEJM PMID original trial everolimus exemestane"})
→ call web_search({"limit":10,"query":"site:pubmed.ncbi.nlm.nih.gov BOLERO-2 everolimus exemestane NEJM PMID"})
→ call pubmed_search({"limit":10,"query":"everolimus exemestane NEJM PMID BOLERO-2"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0108-transcript", "tags": "iteration transcript", "modified": "20260424214156000", "preview": "!! 第 108 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 NEXT_FOCUS original human trial\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0010-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424175830000\", \"preview\": \"!! 第 10 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS PMID 10 条候选 研究类型 保留 排除 理由\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"evidence-retrieval clinical-trials\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0051-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424194527000\", \"preview\": \"!! 第 51 轮执行"}, {"title": "Iter-4360dd15-0078-transcript", "tags": "iteration transcript", "modified": "20260424203248000", "preview": "!! 第 78 轮执行轨迹 【tool:web_search】
{"ok": true, "query": "site:pubmed.ncbi.nlm.nih.gov BOLERO-2 everolimus exemestane NEJM PMID", "results": [{"title": "The BOLERO-2 trial: the addition of everolimus to exemestane in the ...", "url": "https://pubmed.ncbi.nlm.nih.gov/22764762/", "snippet": "The BOLERO-2 trial examined the effects on progression-free survival of the addition of everolimus to exemestane in a patient population of postmenopausal, hormone receptor-positive, advanced breast cancer."}, {"title": "Everolimus plus exemestane for the treatment of advanced ... - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/25810012/", "snippet": "This review will summarize the overall findings from BOLERO-2 and will consider available subanalyses by age, Asian origin, visceral or bone metastases, and prior therapy, with the aim of identifying populations most likely to benefit from everolimus therapy."}, {"title": "Efficacy and safety of everolimus plus exemestane in ... - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/29992557/", "snippet": "The ORR in 4EVER was lower than in BOLERO-2 , likely due to inclusion of patients with more advanced disease and extensive pretreatment. These data confirm the clinical benefits and known safety profile of everolimus plus exemestane in postmenopausal women with HR+, HER2- aBC."}, {"title": "Everolimus for women with trastuzumab-resistant, HER2-positive ...", "url": "https://pubmed.ncbi.nlm.nih.gov/24742739/", "snippet": "The addition of everolimus to trastuzumab plus vinorelbi
【tool:pubmed_search】
{"ok": true, "query": "everolimus exemestane NEJM PMID BOLERO-2", "results": []}
→ call web_search({"limit":10,"query":"\"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer\" PMID 2012"})
→ call pubmed_search({"limit":10,"query":"\"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer\""})
→ call web_search({"limit":10,"query":"\"BOLERO-2\" \"primary endpoint\" PFS PMID 2012"})
【tool:web_search】
{"ok": true, "query": "\"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer\" PMID 2012", "results": [{"title": "Everolimus in postmenopausal hormone-receptor-positive advanced breast ...", "url": "https://www.bordet.be/en/everolimus-postmenopausal-hormone-receptor-positive-advanced-breast-cancer", "snippet": "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer ."}]}
【tool:pubmed_search】
{"ok": true, "query": "\"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer\"", "results": [{"pmid": "39379960", "title": "Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER(+) breast cancer.", "source": "BMC Med", "pubdate": "2024 Oct 8", "authors": ["Zimmer P", "Esser T", "Lueftner D", "Schuetz F", "Baumann FT", "Rody A", "Schneeweiss A", "Hartkopf AD"], "url": "https://pubmed.ncbi.nlm.nih.gov/39379960/"}, {"pmid": "38447007", "title": "Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.", "source": "Int J Cancer", "pubdate": "2024 Jul 1", "authors": ["Lüftner D", "Schuetz F", "Schneeweiss A", "Hartkopf A", "Bloch W", "Decker T", "Uleer C", "Stötzer O"], "url": "https://pubmed.ncbi.nlm.nih.gov/38447007/"}, {"pmid": "37655108", "title": "Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis.", "source": "Front Oncol", "pubdate": "2023", "authors": ["Chao TC", "Tsai YF", "Liu CY", "Lien PJ", "Lin YS", "Feng CJ", "Chen YJ", "Lai JI"], "url": "https://pubmed.ncbi.nlm.nih.gov/37655108/"}, {"pmid": "36823129", "title": "Effectiveness of Changing the Class of Molecularly Targeted Agent after Disease Progression during Initial Molecularly Targeted Therapy fo
【tool:web_search】
{"ok": true, "query": "\"BOLERO-2\" \"pri
```